Stock Events

Stock Events

Scynexis 

€0.000000
55
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q1 2026
Next
-2.85
-2.05
-1.25
-0.44
Expected EPS
-0.44296882475999994
Actual EPS
N/A

Financials

-43.8%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
17.57MRevenue
-7.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 135.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap305.1B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap201.93B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap103.32B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
ISIN
US8112923094

Listings

STU
DE
135.STU
F
DE
135.F
MU
DE
135.MU
XNAS
US
SCYX

0 Comments

Share your thoughts

FAQ

What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker 135.STU.
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on August 17, 2026.
What were Scynexis earnings last quarter?▼
135.STU earnings for the last quarter are -2.85 EUR per share, whereas the estimation was -0.84 EUR resulting in a -240.54% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 17.57M EUR.
What is Scynexis net income for the last year?▼
135.STU net income for the last year is -7.7M EUR.
In which sector is Scynexis located?▼
Scynexis operates in the Other sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on June 01, 2026 with a ratio of 1:8.